Tissue‐resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression
暂无分享,去创建一个
Wei Wu | Tianjiao Li | Longyun Ye | Xuan Lin | K. Jin | Xing Jin | Xianjun Yu | Qinglin Fei | Saimeng Shi | Huiru Zhang | Zhenyu Liao | L. Ye | Hui-Ru Zhang
[1] Zhenyu Liao,et al. Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer , 2022, EBioMedicine.
[2] Zhenyu Liao,et al. Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21 , 2021, Cancers.
[3] C. Rao,et al. Naproxen inhibits spontaneous lung adenocarcinoma formation in KrasG12V mice , 2021, Neoplasia.
[4] Shanshan Li,et al. Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression , 2021, Hepatology.
[5] Jianguo Wang,et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy , 2021, Signal Transduction and Targeted Therapy.
[6] Wen-quan Wang,et al. Human splenic TER cells: A relevant prognostic factor acting via the artemin‐GFRα3‐ERK pathway in pancreatic ductal adenocarcinoma , 2020, International journal of cancer.
[7] Jessica S. Yu,et al. Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer , 2020, Nature Cancer.
[8] G. Miller,et al. Regulation and modulation of antitumor immunity in pancreatic cancer , 2020, Nature Immunology.
[9] Stephen M. Shaw,et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial , 2020, Nature Medicine.
[10] A. Maitra,et al. Pancreatic cancer stroma: an update on therapeutic targeting strategies , 2020, Nature Reviews Gastroenterology & Hepatology.
[11] L. Jones,et al. Fibronectin acts as a molecular switch to determine SPARC function in pancreatic cancer. , 2020, Cancer letters.
[12] M. Bajénoff,et al. Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer , 2020, The Journal of experimental medicine.
[13] Le Xu,et al. Tumor-infiltrating TNFRSF9+ CD8+ T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response , 2020, Oncoimmunology.
[14] M. Vignali,et al. Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer , 2019, Clinical Cancer Research.
[15] Alexander H. E. Morrison,et al. Immunotherapy and Prevention of Pancreatic Cancer. , 2018, Trends in cancer.
[16] M. Hollingsworth,et al. Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy☆ , 2017, Pharmacology & therapeutics.
[17] Jingqin Luo,et al. Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. , 2017, Immunity.
[18] Z. Halpern,et al. Tumor macrophages are pivotal constructors of tumor collagenous matrix , 2016, The Journal of experimental medicine.
[19] Hong Zhao,et al. CXCR4 in breast cancer: oncogenic role and therapeutic targeting , 2015, Drug design, development and therapy.
[20] W. Knoefel,et al. CXCR4-A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis , 2015, PloS one.
[21] Jeffrey W Pollard,et al. Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.
[22] J. Pollard,et al. A Lineage of Myeloid Cells Independent of Myb and Hematopoietic Stem Cells , 2012, Science.
[23] Beverly A. Teicher,et al. CXCL12 (SDF-1)/CXCR4 Pathway in Cancer , 2010, Clinical Cancer Research.
[24] M. Colombo,et al. Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. , 2008, Cancer research.